Literature DB >> 27981365

Association of worry about cancer to benefit finding and functioning in long-term cancer survivors.

Salene M W Jones1, Rebecca Ziebell2, Rod Walker2, Larissa Nekhlyudov3, Borsika A Rabin4, Stephanie Nutt5, Monica Fujii2, Jessica Chubak2.   

Abstract

PURPOSE: Worry about cancer recurrence or progression is associated with negative effects of cancer, such as worse physical functioning, but associations with positive changes post-cancer, such as benefit finding, are unknown. We measured the proportion of patients reporting frequent worry about cancer recurrence or progression and examined the association between worry about cancer recurrence or progression to benefit finding and functioning in cancer.
METHODS: We surveyed 594 long-term (5-10 years post-diagnosis) survivors of cancer (breast, prostate, colorectal, lung, melanoma) in this cross-sectional study. The survey asked about worry about cancer recurrence/progression, negative effects of cancer on mental and physical function, and benefit finding as a result of the cancer (positive effects). Multivariate regressions estimated associations of worry about cancer with negative and positive effects of cancer.
RESULTS: Worrying about cancer often or all the time was reported by 19.6% of survivors. Worry about cancer was related to worse functioning (odds ratio (OR) range 1.40 to 1.46, all p's < .01). Worry about recurrence/progression was unrelated to benefit finding (all p's > .10).
CONCLUSIONS: Worry about cancer was associated with negative, but not positive, effects of cancer. Treating worry about cancer is unlikely to reduce benefit finding after cancer. Given the high prevalence of worry about cancer and relationship to negative effects of cancer, clinical care should attempt to address this worry for long-term survivors.

Entities:  

Keywords:  Fear of recurrence; Neoplasm; Post-traumatic growth; Survivorship; Worry

Mesh:

Year:  2016        PMID: 27981365     DOI: 10.1007/s00520-016-3537-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  35 in total

Review 1.  Design strategies and innovations in the medical expenditure panel survey.

Authors:  Steven B Cohen
Journal:  Med Care       Date:  2003-07       Impact factor: 2.983

Review 2.  Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies.

Authors:  L Koch; L Jansen; H Brenner; V Arndt
Journal:  Psychooncology       Date:  2012-01-10       Impact factor: 3.894

Review 3.  Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies.

Authors:  Sébastien Simard; Belinda Thewes; Gerry Humphris; Mélanie Dixon; Ceara Hayden; Shab Mireskandari; Gozde Ozakinci
Journal:  J Cancer Surviv       Date:  2013-03-10       Impact factor: 4.442

4.  Changes in emotion regulation and psychological adjustment following use of a group psychosocial support program for women recently diagnosed with breast cancer.

Authors:  Linda D Cameron; Roger J Booth; Melanie Schlatter; Danute Ziginskas; John E Harman
Journal:  Psychooncology       Date:  2007-03       Impact factor: 3.894

5.  The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement.

Authors:  K Robin Yabroff; Emily Dowling; Juan Rodriguez; Donatus U Ekwueme; Helen Meissner; Anita Soni; Catherine Lerro; Gordon Willis; Laura P Forsythe; Laurel Borowski; Katherine S Virgo
Journal:  J Cancer Surviv       Date:  2012-07-19       Impact factor: 4.442

Review 6.  Evaluating direct medical expenditures estimation methods of adults using the medical expenditure panel survey: an example focusing on head and neck cancer.

Authors:  Diarmuid Coughlan; Susan T Yeh; Ciaran O'Neill; Kevin D Frick
Journal:  Value Health       Date:  2014 Jan-Feb       Impact factor: 5.725

Review 7.  Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V.

Authors:  Gavin Andrews; Megan J Hobbs; Thomas D Borkovec; Katja Beesdo; Michelle G Craske; Richard G Heimberg; Ronald M Rapee; Ayelet Meron Ruscio; Melinda A Stanley
Journal:  Depress Anxiety       Date:  2010-02       Impact factor: 6.505

8.  Psychometric investigation of benefit finding among long-term cancer survivors using the Medical Expenditure Panel Survey.

Authors:  Salene M W Jones; Rebecca Ziebell; Rod Walker; Larissa Nekhlyudov; Borsika A Rabin; Stephanie Nutt; Monica Fujii; Jessica Chubak
Journal:  Eur J Oncol Nurs       Date:  2015-07-26       Impact factor: 2.398

9.  Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.

Authors:  Zhiyuan Zheng; K Robin Yabroff; Gery P Guy; Xuesong Han; Chunyu Li; Matthew P Banegas; Donatus U Ekwueme; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2015-12-24       Impact factor: 13.506

10.  Study protocol of the SWORD-study: a randomised controlled trial comparing combined online and face-to-face cognitive behaviour therapy versus treatment as usual in managing fear of cancer recurrence.

Authors:  Marieke A van de Wal; Marieke Fm Gielissen; Petra Servaes; Hans Knoop; Anne Em Speckens; Judith B Prins
Journal:  BMC Psychol       Date:  2015-04-16
View more
  2 in total

1.  Health anxiety and illness-related fears across diverse chronic illnesses: A systematic review on conceptualization, measurement, prevalence, course, and correlates.

Authors:  Sophie Lebel; Brittany Mutsaers; Christina Tomei; Caroline Séguin Leclair; Georden Jones; Danielle Petricone-Westwood; Nicole Rutkowski; Viviane Ta; Geneviève Trudel; Simone Zofia Laflamme; Andrée-Anne Lavigne; Andreas Dinkel
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

2.  Predictors and interdependence of family support in a random sample of long-term young breast cancer survivors and their biological relatives.

Authors:  Maria C Katapodi; Katrina R Ellis; Franziska Schmidt; Christos Nikolaidis; Laurel L Northouse
Journal:  Cancer Med       Date:  2018-09-05       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.